Insilico Medicine publishes 2025 annual report
PUBT·04/28/2026 12:07:04
Listen to the news
- Insilico Medicine annual report for year ended Dec. 31, 2025 highlighted upgrades to Pharma.AI across Biology42, Chemistry42, Science42, including launch of Nach01 on AWS Marketplace.
- Pipeline advanced with 10 assets in clinical development, led by ISM001-055 (Rentosertib) for idiopathic pulmonary fibrosis with Phase IIa results published in Nature Medicine.
- China CDE granted Breakthrough Therapy Designation to Rentosertib, supporting plan to start a Phase III trial in China in 2026.
- Clinical activity broadened with first patient dosed for ISM5411 Phase IIa in China, ISM6331 Phase I in China and US, ISM3412 global Phase I.
- Partnering momentum extended with Eli Lilly collaboration expanded in March 2026, including USD 115 million upfront, up to about USD 2.75 billion total potential value.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260428-12130382), on April 28, 2026, and is solely responsible for the information contained therein.
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.